高质量的患者报告的结果（PRO）数据对于指导共同决策是至关重要的，尤其是在局部复发直肠癌（LRRC）的背景下，治疗潜在的益处必须与对生活质量等PRO的影响相平衡。此次综述的目的是发现目前在LRRC中报告的患者报告的结果（PROMs）并评估使用这些措施的研究的方法论质量。搜索PubMed，Embase和CINAHL数据库，包括到2022年9月14日发表的研究。包括以LRRC为主要或次要终点的成人研究。使用CONSORT-PRO清单和COSMIN偏倚风险清单的标准来提取有关PROM报告的方法学质量和PROM的心理测量性质的数据。共发现了35项研究，包括1914名LRRC患者。回顾中没有任何一项研究符合PROM报告的全部11项标准。发现17项PROM和两项临床医师报告的结果措施，没有一个经过验证可用于LRRC患者。目前用于报告LRRC中PRO的PROM均未经过验证适用于这组患者。未来在这个疾病领域的研究应该着重于利用经过严格开发过程的PROM，包括LRRC患者，以产生高质量、准确、相关的数据。©2023.作者（们）。

The availability of high-quality patient-reported outcome (PRO) data is crucial to guiding shared decision-making in the context of locally recurrent rectal cancer (LRRC), where potential treatment benefits must be balanced against the impact of both the disease and treatment on PROs, such as quality of life. This review aimed to identify the patient-reported outcome measures (PROMs) currently being reported in LRRC and to appraise the methodological quality of studies using these measures.PubMed, Embase and CINAHL databases were searched, including studies published up until 14th September 2022. Studies in adults with LRRC reporting PROMS as a primary or secondary outcome measure were included. Data were extracted concerning the methodological quality of the reporting of PROMs using criteria informed by the CONSORT-PRO checklist and the psychometric properties of the PROMs identified using the COSMIN Risk of Bias checklist.Thirty-five studies including 1914 patients with LRRC were identified. None of the studies included in the review met all eleven criteria for the quality of reporting of PROMs. Seventeen PROMs and two clinician-reported outcome measures were identified, none of which have been validated for use in patients with LRRC.None of the PROMs which are currently being used to report PROs in LRRC have been validated for use in this cohort of patients. Future studies in this disease area should focus on utilising PROMs that have undergone a robust development process including patients with LRRC, to produce data which is high quality, accurate and relevant.© 2023. The Author(s).